Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Aug 13:11:1850.
doi: 10.3389/fmicb.2020.01850. eCollection 2020.

Azole-Resistant Aspergillus fumigatus Among Danish Cystic Fibrosis Patients: Increasing Prevalence and Dominance of TR34/L98H

Affiliations

Azole-Resistant Aspergillus fumigatus Among Danish Cystic Fibrosis Patients: Increasing Prevalence and Dominance of TR34/L98H

Malene Risum et al. Front Microbiol. .

Abstract

Azole-resistant (azole-R) Aspergillus is an increasing challenge worldwide. Patients with cystic fibrosis (CF) are at risk of Aspergillus colonization and disease due to a favorable lung environment for microorganisms. We performed a nationwide study in 2018 of azole-non-susceptible Aspergillus in CF patients and compared with data from two prior studies. All airway samples with mold isolates from patients monitored at the two CF centers in Denmark (RH, Jan-Sept and AUH, Jan-Jun) were included. Classical species identification (morphology and thermo-tolerance) was performed and MALDI-TOF/β-tubulin sequencing was performed if needed. Susceptibility was determined using EUCAST E.Def 10.1, and E.Def 9.3.2. cyp51A sequencing and STRAf genotyping were performed for azole-non-susceptible isolates and relevant sequential isolates. In total, 340 mold isolates from 159 CF patients were obtained. The most frequent species were Aspergillus fumigatus (266/340, 78.2%) and Aspergillus terreus (26/340, 7.6%). Azole-R A. fumigatus was cultured from 7.3% (10/137) of patients, including 9.5% (9/95) of patients at RH and 2.4% at AUH (1/42), respectively. In a 10-year perspective, azole-non-susceptibility increased numerically among patients at RH (10.5% in 2018 vs 4.5% in 2007-2009). Cyp51A resistance mechanisms were found in nine azole-R A. fumigatus from eight CF patients. Five were of environmental origin (TR34/L98H), three were human medicine-driven (two M220K and one M220R), and one was novel (TR34 3/L98H) and found in a patient who also harbored a TR34/L98H isolate. STRAf genotyping identified 27 unique genotypes among 45 isolates and ≥2 genotypes in 8 of 12 patients. This included one patient carrying two unique TR34/L98H isolates, a rare phenomenon. Genotyping of sequential TR34 3/L98H and TR34/L98H isolates from the same patient showed only minor differences in 1/9 markers. Finally, azole-R A. terreus was found in three patients including two with Cyp51A alterations (M217I and G51A, respectively). Azole-R A. fumigatus is increasing among CF patients in Denmark with the environmentally associated resistance TR34/L98H mechanism being dominant. Mixed infections (wildtype/non-wildtype and several non-wildtypes) and a case of potential additional tandem repeat acquisition in vivo were found. However, similar genotypes were identified from another patient (and outside this study), potentially suggesting a predominant TR34/L98H clone in DK. These findings suggest an increasing prevalence and complexity of azole resistance in A. fumigatus.

Keywords: Aspergillus; azoles; cystic fibrosis; mutation; resistance.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Species distribution at the cystic fibrosis population gathered and at the two centers separately. S, I, and R indicate the susceptibility for azoles. S: susceptible, I: intermediate, and R: resistant. Aarhus (AUH): Other molds: Scedosporium spp. (n = 8), Exophiala spp. (n = 2), Penicillium spp. (n = 1). Rigshospitalet (RH): Other Aspergillus: Aspergillus nidulans (n = 2) and Aspergillus sydowii (n = 1), Mucorales: Rhiomucor pusillus (n = 1) and Zygomycetes spp. (n = 1). Other molds: Scedosporium spp. (n = 3), and Rasamsonia spp. (n = 1).

Similar articles

Cited by

References

    1. Abdolrasouli A., Scourfield A., Rhodes J., Shah A., Elborn J. S., Fisher M. C., et al. (2018). High prevalence of triazole resistance in clinical Aspergillus fumigatus isolates in a specialist cardiothoracic centre. Int. J. Antimicrob. Agents 52 637–642. 10.1016/j.ijantimicag.2018.08.004 - DOI - PubMed
    1. Amorim A., Guedes-Vaz L., Araujo R. (2010). Susceptibility to five antifungals of Aspergillus fumigatus strains isolated from chronically colonised cystic fibrosis patients receiving azole therapy. Int. J. Antimicrob. Agents 35 396–399. 10.1016/j.ijantimicag.2009.12.007 - DOI - PubMed
    1. Arendrup M. C., Cuenca-Estrella M., Lass-Flörl C., Hope W. W. (2013). Breakpoints for antifungal agents: An update from EUCAST focussing on echinocandins against Candida spp. and triazoles against Aspergillus spp. Drug Resist. Updat. 16 81–95. 10.1016/j.drup.2014.01.001 - DOI - PubMed
    1. Arendrup M. C., Jensen R. H., Grif K., Skov M., Pressler T., Johansen H. K., et al. (2012). In vivo emergence of Aspergillus terreus with reduced azole susceptibility and a Cyp51a M217I alteration. J. Infect. Dis. 206 981–985. 10.1093/infdis/jis442 - DOI - PubMed
    1. Arendrup M. C., Meletiadis J., Mouton J. W., Guinea J., Cuenca-Estrella M., Lagrou K., et al. (2016). EUCAST technical note on isavuconazole breakpoints for Aspergillus, itraconazole breakpoints for Candida and updates for the antifungal susceptibility testing method documents. Clin. Microbiol. Infect. 22, 571.e1–571.e4. 10.1016/j.cmi.2016.01.017 - DOI - PubMed